Reviewed by Michael Gill, B. Sc.
17 Anaplastic Astrocytoma Clinical Trials Near Me
Top Hospitals for Anaplastic Astrocytoma Clinical Trials
Image of Northwestern University in Illinois.
Northwestern University
Chicago
3Active Trials
11All Time Trials for Anaplastic Astrocytoma
2004First Anaplastic Astrocytoma Trial
Image of Dana Farber Cancer Institute in Massachusetts.
Dana Farber Cancer Institute
Boston
3Active Trials
9All Time Trials for Anaplastic Astrocytoma
2005First Anaplastic Astrocytoma Trial
Top Cities for Anaplastic Astrocytoma Clinical Trials
Anaplastic Astrocytoma Clinical Trials by Phase of Trial
Most Recent Anaplastic Astrocytoma Clinical Trials
Top Treatments for Anaplastic Astrocytoma Clinical Trials
Treatment Name
Active Anaplastic Astrocytoma Clinical Trials
All Time Trials for Anaplastic Astrocytoma
First Recorded Anaplastic Astrocytoma Trial
dabrafenib
2
2
2017
Craniotomy
1
1
2023
Randomized Perioperative Phase: Vorasidenib Only
1
1
2022
temporally-modulated pulsed radiotherapy (TMPRT)
1
1
2022
Retifanlimab
1
1
2022
Recently Completed Studies with FDA Approved Treatments for Anaplastic Astrocytoma
Treatment
Year
Sponsor
Neural stem cells loaded with an oncolytic adenovirus
2017
Northwestern University
Dendritic Cell Vaccine
2013
Macarena De La Fuente, MD

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 30th, 2021

Last Reviewed: November 8th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. https://pubmed.ncbi.nlm.nih.gov/177051752 Shahid S, Kushner BH, Modak S, Basu EM, Rubin EM, Gundem G, Papaemmanuil E, Roberts SS. Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastoma. Pediatr Blood Cancer. 2021 Oct;68(10):e29265. doi: 10.1002/pbc.29265. Epub 2021 Jul 31. https://pubmed.ncbi.nlm.nih.gov/343315153 Blyth BJ, Farhavar A, Gee C, Hawthorn B, He H, Nayak A, Stöcklein V, Bazarian JJ. Validation of serum markers for blood-brain barrier disruption in traumatic brain injury. J Neurotrauma. 2009 Sep;26(9):1497-1507. doi: 10.1089/neu.2008-0738. https://pubmed.ncbi.nlm.nih.gov/192578034 Petronio J, Edwards MS, Prados M, Freyberger S, Rabbitt J, Silver P, Levin VA. Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. J Neurosurg. 1991 May;74(5):701-8. https://pubmed.ncbi.nlm.nih.gov/19015975 Bai RY, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol. 2011 Sep;13(9):974-82. doi: 10.1093/neuonc/nor077. Epub 2011 Jul 15. https://pubmed.ncbi.nlm.nih.gov/217648226 Sievert AJ, Fisher MJ. Pediatric low-grade gliomas. J Child Neurol. 2009 Nov;24(11):1397-408. doi: 10.1177/0883073809342005. Review. https://pubmed.ncbi.nlm.nih.gov/198414287 Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. https://pubmed.ncbi.nlm.nih.gov/177051758 Duffner PK, Horowitz ME, Krischer JP, Friedman HS, Burger PC, Cohen ME, Sanford RA, Mulhern RK, James HE, Freeman CR, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993 Jun 17;328(24):1725-31. https://pubmed.ncbi.nlm.nih.gov/83885489 Gajjar A, Sanford RA, Heideman R, Jenkins JJ, Walter A, Li Y, Langston JW, Muhlbauer M, Boyett JM, Kun LE. Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital. J Clin Oncol. 1997 Aug;15(8):2792-9. https://pubmed.ncbi.nlm.nih.gov/925612110 Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, Wara W, MacDonald D, Stitt L, Cairncross JG. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9. https://pubmed.ncbi.nlm.nih.gov/10571199